CD270 (HVEM), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD270 (HVEM), Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD270 (HVEM), Human |
| Clone | REAL846 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | n/a |
| Format | phycoerythrin (PE) conjugate |
| Size | 200 µL |
| Concentration | n/a |
| Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD270 (HVEM) Antibody, anti-human, PE, REAdye_lease™. Clone REAL846 is an antibody fragment derived from the full CD270 (HVEM) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL846 recognizes CD270, which is also known as HVEM or TNFRSF14 (Tumor necrosis factor receptor superfamily member 14). CD270 derives its name based on the ability of types 1 and 2 herpesvirus gD to bind to it for entry into the cell. CD270 is a type 1 transmembrane protein with a predicted molecular weight of 30 kDa and is a member of TNFR superfamily. CD270 transmits both activating and inhibitory signals for, e.g., interaction with receptors such as BTLA or CD160 attenuates TCR-mediated signaling, whereas interaction with receptor LIGHT allows co-stimulation of T and B cells. Expression of CD270 is widely distributed and is found on hematopoietic cells such as dendritic cells, Tregs, monocytes, neutrophils, NK cells, B cells, and T cells, as well as on non-hematopoietic cells. Lymphomas, malignant melanomas and cases of prostate, colorectal, renal and urothelial cancers displayed moderate to strong cytoplasmic staining. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). |
| Immunogen | n/a |
| Other Names | TNFRSF14, ATAR, HVEA, HVEM, LIGHTR, TR2 |
| Gene, Accession # | n/a |
| Catalog # | 130-126-217 |
| Price | $470 |
| Order / More Info | CD270 (HVEM), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Ware, C. F. et al. (2009) Targeting the LIGHT-HVEM pathway. Adv. Exp. Med. Biol. 647: 146-155. | Pasero, C. et al. (2012) The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. Curr. Opin. Pharmacol. 12 (4): 478-485. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG